Nihon Kagaku Sangyo Co 4094.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 4094.T. It has been listed since 2 October 1961. In the fiscal year to 31 March 2026, it reported revenue of ¥28.03bn and net income of ¥2.28bn. At that date it held total assets of ¥61.69bn and shareholders' equity of ¥50.82bn.

Nihon Kagaku Sangyo Co., Ltd. engages in the production and sale of industrial chemicals and building materials. The company is headquartered in Taito-Ku, Tokyo-To. The firm operates in two business segments. The Chemicals segment is engaged in the manufacture and sale of metal compounds such as copper, tin, nickel and cobalt chemicals, metal soaps such as octylic acid, battery chemicals, gloss agents and additives for surface treatment, and electroless nickel plating liquids, as well as the processing of cathode materials for secondary batteries, and the plating processing business. The Building Materials segment is engaged in the manufacture and sale of house building products such as fireproof ventilation corner beads, seismic reinforcing materials, interior partition walls, post boxes, balustrades and copings, metal shutters, as well as heat-exchange equipment and others.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Eiji YanagisawaChairman of the Board, since 2003
• Mr. Hiroki KadoyaPresident, Chief Senior Director of Pharmaceutical Business, Representative Director, since 2019
• Mr. Takeyuki OhtaSenior Managing Executive Officer, Chief Director of Administration, Director, since 2019
• Mr. Akira YamamotoManaging Executive Officer, Director, since 2023
• Mr. Osamu MatsuoManaging Executive Officer
• Mr. Isao OnomuraManaging Executive Officer, since 2016
• Mr. Osamu YamadaManaging Executive Officer, Chief Director of Pharmaceutical Sales in Main Pharmaceutical Business Supervision Unit, Director of Marketing, since 2016
• Mr. Yuzuru MomoseExecutive Officer, Director of General Affairs in Main Administration Unit
• Mr. Yuzuru SugawaraExecutive Officer
• Mr. Juntaka WatanabeExecutive Officer, Manager of R&D Center in Main Pharmaceutical Business Supervision Unit, Director of Research
• Mr. Takeshi HachimuraIndependent Director
• Mr. Asaka KandaIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.